Opthea Limited (OPT)

NASDAQ: OPT · IEX Real-Time Price · USD
3.94
+0.01 (0.25%)
Mar 31, 2023, 11:51 AM EDT - Market open
0.25%
Market Cap 229.96M
Revenue (ttm) 138,198
Net Income (ttm) -64.46M
Shares Out 58.36M
EPS (ttm) -1.47
PE Ratio n/a
Forward PE 6.73
Dividend n/a
Ex-Dividend Date n/a
Volume 1,952
Open 3.91
Previous Close 3.93
Day's Range 3.91 - 3.96
52-Week Range 3.91 - 8.50
Beta 0.31
Analysts Buy
Price Target 9.16 (+132.49%)
Earnings Date n/a

About OPT

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 16, 2020
Country Australia
Stock Exchange NASDAQ
Ticker Symbol OPT
Full Company Profile

Financial Performance

In 2022, Opthea's revenue was 199,005, an increase of 108.24% compared to the previous year's 95,563. Losses were -92.82 million, 104.7% more than in 2021.

Financial numbers in AUD Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for OPT stock is "Buy." The 12-month stock price forecast is $9.16, which is an increase of 132.49% from the latest price.

Price Target
$9.16
(132.49% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Opthea Receives A$8.7 million R&D Tax Incentive

MELBOURNE, Australia, March 07, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progr...

3 weeks ago - GlobeNewsWire

Opthea To Participate in Fireside Chat at Oppenheimer's 33rd Annual Healthcare Conference

MELBOURNE, Australia, March 06, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progr...

3 weeks ago - GlobeNewsWire

Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD Published in the Journal Ophthalmology

MELBOURNE, Australia, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...

1 month ago - GlobeNewsWire

Opthea To Present at SVB Leerink Global Biopharma Conference

MELBOURNE, Australia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...

1 month ago - GlobeNewsWire

Opthea To Present at Sequire Biotechnology Conference

MELBOURNE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...

2 months ago - GlobeNewsWire

Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD

MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...

3 months ago - GlobeNewsWire

Opthea to Present at the FLORetina 2022 Congress

MELBOURNE, Australia, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...

4 months ago - GlobeNewsWire

Opthea to Present at Jefferies London Healthcare Conference

MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...

5 months ago - GlobeNewsWire

Opthea Expands Leadership Team with the Appointment of Timothy E. Morris as Chief Financial Officer

MELBOURNE, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...

5 months ago - GlobeNewsWire

Opthea Reports Fiscal Year 2022 Financial Results and Corporate Highlights

Secured up to US$170m in non-dilutive financing

7 months ago - GlobeNewsWire

Opthea Announces Presentation at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

MELBOURNE, Australia, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...

8 months ago - GlobeNewsWire

Opthea Successfully Closes Well Supported US$90 Million Equity Financing

MELBOURNE, Australia, Aug. 14, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ: OPT) (Opthea), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent ...

8 months ago - GlobeNewsWire

Opthea Secures up to US$170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

MELBOURNE, Australia and BOSTON, Aug. 14, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX: OPT; NASDAQ: OPT), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevale...

8 months ago - GlobeNewsWire

Opthea To Present at Upcoming Investor Conferences

MELBOURNE, Australia, May 11, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal...

11 months ago - GlobeNewsWire

Opthea Presentation at The Retina World Congress 2022

MELBOURNE, Australia, May 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progres...

11 months ago - GlobeNewsWire

Opthea Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) Presented at ARVO 2022

MELBOURNE, Australia., May 05, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progr...

11 months ago - GlobeNewsWire

Opthea Presenting Clinical Data at ARVO 2022 Annual Meeting

MELBOURNE, Australia, April 29, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progr...

1 year ago - GlobeNewsWire

Opthea strengthens its Board of Directors

Elects Mr. Quinton Oswald and Dr. Susan Orr, deeply experienced Ophthalmology Executives, at a General Meeting of Shareholders Elects Mr. Quinton Oswald and Dr. Susan Orr, deeply experienced Ophthalmo...

1 year ago - GlobeNewsWire

Opthea To Present at Oppenheimer's 32nd Annual Healthcare Conference

MELBOURNE, Australia, March 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retin...

1 year ago - GlobeNewsWire

Opthea Expands Leadership Team with the Appointment of Joel Naor, M.D., M.Sc., MBA as Chief Medical Officer

MELBOURNE, Australia, March 02, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progr...

1 year ago - GlobeNewsWire

Opthea Shares OPT-302 data In Patients With Subtype Of Age-Related Macular Degeneration

Opthea Limited's (NASDAQ: OPT) OPT-302 data were presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference.  The data presented was a prespecified subgroup a...

1 year ago - Benzinga

Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022

Professor Gemmy Cheung, Singapore Eye Research Institute, presented prespecified subgroup analysis of PCV patients enrolled in Opthea's Phase 2b clinical trial of OPT-302 in combination with ranibizum...

1 year ago - GlobeNewsWire

Opthea To Present at SVB Leerink Global Healthcare Conference

MELBOURNE, Australia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...

1 year ago - GlobeNewsWire

Opthea Announces Presentation at the Angiogenesis, Exudation, and Degeneration 2022 Conference

MELBOURNE, Australia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...

1 year ago - GlobeNewsWire

Opthea Receives A$6.6 m R&D Tax Incentive

MELBOURNE, Australia, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...

1 year ago - GlobeNewsWire